Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/161569
Title: Topical Pioglitazone Nanoformulation for the Treatment of Atopic Dermatitis: Design, Characterization and Efficacy in Hairless Mouse Model
Author: Espinoza, Lupe Carolina
Vera-García, Rodrigo
Silva Abreu, Marcelle
Domènech, Òscar
Badía Palacín, Josefa
Rodríguez Lagunas, María José
Clares Naveros, Beatriz
Calpena Campmany, Ana Cristina
Keywords: Dermatitis atòpica
Farmacologia experimental
Disseny de medicaments
Atopic dermatitis
Experimental pharmacology
Drug design
Issue Date: 12-Mar-2020
Publisher: MDPI
Abstract: Pioglitazone (PGZ) is a drug used to treat type 2 diabetes mellitus that has been reported to show additional therapeutic activities on diverse inflammatory parameters. The aim of this study was to optimize a topical PGZ-loaded nanoemulsion (PGZ-NE) in order to evaluate its effectiveness for treating atopic dermatitis (AD). The composition of the nanoformulation was established by pseudo-ternary diagram. Parameters such as physical properties, stability, in vitro release profile, and ex vivo permeation were determined. The efficacy study was carried out using oxazolone-induced AD model in hairless mice. PGZ-NE released the drug following a hyperbolic kinetic. Additionally, its properties provided high retention potential of drug inside the skin. Therapeutic benefits of PGZ-NE were confirmed on diverse events of the inflammatory process, such as reduction of lesions, enhancement of skin barrier function, diminished infiltration of inflammatory cells, and expression of pro-inflammatory cytokines. These results were reinforced by atomic force microscope (AFM), which demonstrated the ability of the formulation to revert the rigidification caused by oxazolone and consequently improve the elasticity of the skin. These results suggest that PGZ-NE may be a promising treatment for inflammatory dermatological conditions such as AD
Note: Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics12030255
It is part of: Pharmaceutics, 2020, vol. 12, num. 3, p. 255
URI: http://hdl.handle.net/2445/161569
Related resource: https://doi.org/10.3390/pharmaceutics12030255
ISSN: 1999-4923
Appears in Collections:Articles publicats en revistes (Bioquímica i Fisiologia)
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
699943.pdf2.13 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons